Tourmaline Bio Inc. Asset Resilience Ratio
Tourmaline Bio Inc. asset resilience ratio. Tourmaline Bio Inc. (TRML) has an Asset Resilience Ratio of 77.17% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Tourmaline Bio Inc. to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Tourmaline Bio Inc. (2020–2024)
Asset resilience ratio of Tourmaline Bio Inc. from 2020 to 2024. This chart shows how Tourmaline Bio Inc.'s Asset Resilience Ratio has changed over time. Read total liabilities of Tourmaline Bio Inc. for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Tourmaline Bio Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Tourmaline Bio Inc. balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $207.81 Million | 77.17% |
| Total Liquid Assets | $207.81 Million | 77.17% |
Asset Resilience Insights
- Very High Liquidity: Tourmaline Bio Inc. maintains exceptional liquid asset reserves at 77.17% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Tourmaline Bio Inc. Industry Peers by Asset Resilience Ratio
Compare Tourmaline Bio Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Tourmaline Bio Inc. Asset Resilience Ratio by Year (2020–2024)
Tourmaline Bio Inc. asset resilience ratio by year from 2020 to 2024. The table below shows the annual Asset Resilience Ratio data for Tourmaline Bio Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 73.72% | $227.80 Million | $309.00 Million | +44.13pp |
| 2023-12-31 | 29.59% | $62.23 Million | $210.29 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $9.10 Million | -- |
| 2021-12-31 | 89.63% | $225.36 Million | $251.42 Million | +3.30pp |
| 2020-12-31 | 86.33% | $131.90 Million | $152.78 Million | -- |
About Tourmaline Bio Inc.
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline c… Read more